<SEC-DOCUMENT>0001193125-21-183248.txt : 20210607
<SEC-HEADER>0001193125-21-183248.hdr.sgml : 20210607
<ACCEPTANCE-DATETIME>20210604200531
ACCESSION NUMBER:		0001193125-21-183248
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210604
FILED AS OF DATE:		20210607
DATE AS OF CHANGE:		20210604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		21997961

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d160476d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 4, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d160476dex991.htm">Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021</A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 4, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d160476dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g160476g26d87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reports Positive Data from its </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II Study of <FONT STYLE="white-space:nowrap">LAG-3</FONT> Therapy, Efti, at ASCO 2021
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination therapy with eftilagimod alpha and pembrolizumab demonstrates very favourable overall response rate
(ORR) together with favourable duration and depth of responses in 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line NSCLC (41.7%, 2 CRs; minimum DoR &gt; 6 months) and 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> line HNSCC
(29.7% ORR, 5 CRs; minimum DoR &gt; 6 months) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tumor responses seen in all <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups, including low <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expressing patients (i.e. patients with TPS &lt; 50%) which are typically less responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Secondary endpoints including progression free survival (PFS) and overall survival (OS) are trending very
favourably in both indications (e.g. median PFS in 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line NSCLC is 8.2 months and median OS in 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> line HNSCC is 12.6 months)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination therapy is safe and well tolerated </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 4</B><B></B><B>&nbsp;June</B><B> 2021 &#150;</B><U> Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy treatments for cancer and autoimmune disease, announces new interim data from its Phase II
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> study (also designated <FONT STYLE="white-space:nowrap">KEYNOTE-798)</FONT> with a data <FONT STYLE="white-space:nowrap">cut-off</FONT> date of 16&nbsp;April 2021. The data will be presented in two
poster presentations by Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, Australia and Dr Irene Brana, Investigator, Vall d&#146;Hebron Institute of Oncology, Barcelona, Spain at the American Society of Clinical Oncology&#146;s
(ASCO) 2021 Annual Meeting in <FONT STYLE="white-space:nowrap">on-demand</FONT> sessions available from 9 am on 4&nbsp;June 2021, US Eastern Time at this year&#146;s virtual conference. The posters will also be made available on Immutep&#146;s
website from that time at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://www.immutep.com/investors-media/presentations.html </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> is being conducted in collaboration with Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA (known as
&#147;MSD&#148; outside the United States and Canada). The study is evaluating the combination of Immutep&#146;s lead product candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;) with MSD&#146;s KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in up to 183 patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> and 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> line (Parts A and B, respectively) or 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> line head and neck squamous cell carcinoma (HNSCC, Part C). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO and CMO, Dr Frederic Triebel said:</B> &#147;As more and more industry focus is on <FONT STYLE="white-space:nowrap">LAG-3</FONT> therapies and
it is in the spotlight of this year&#146;s ASCO, we are very pleased to be reporting such robust and exciting results from our <FONT STYLE="white-space:nowrap">TACTI-002</FONT> study of efti in combination with pembrolizumab. We are seeing nearly
50% of the evaluable 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line NSCLC patients responding to the therapy, as scored by a blinded independent central review committee, with responses in all
<FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups and a favourable median PFS. Overall, the NSCLC patients receiving this 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line therapy are living 8.2 months without their disease
progressing, a promising improvement for a chemo-free 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line regimen. In effect, we are seeing an improvement in patient outcomes compared with that historically seen with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy but with a similar safety profile and, also, comparable results in terms of ORR and PFS to chemo + <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> combination therapy but, importantly, with a longer duration of response and lower toxicity.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160476g26d87.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investigator, A/Prof Tim Clay, St John of God
Subiaco Hospital, Perth, Australia said: &#147;</B>The median PFS of 8.2 months in 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line NSCLC patients is very encouraging compared to historical studies where pembrolizumab has been given as
monotherapy in comparable patient groups. There remains a great need for more effective chemotherapy free regimens in the treatment of NSCLC.&nbsp;These data are exciting and as a result, we will be expanding recruitment with 74 additional patients
for Part A.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investigator, Dr Irene </B><B>Brana</B><B>, </B><B>Vall</B><B> </B><B>d&#146;Hebron</B><B> Institute of Oncology, Barcelona, Spain,
said</B>: &#147;The sustained and durable responses reported in 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> line HNSCC patients are improving as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> progresses, with about 14% of patients
now benefiting from a complete disappearance of all their tumour lesions. Responses are particularly good in <FONT STYLE="white-space:nowrap">PD-L1</FONT> expressing patients (CPS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1) where an ORR of
45.8% is reported. The strength of these results validates the decision to explore the combination of efti and pembrolizumab in a new Phase IIb study, <FONT STYLE="white-space:nowrap">TACTI-003</FONT> in 1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> line HNSCC patients which is starting in the coming months.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Table 1</I> &#150; <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> Interim ORR Results for Part A and C (data <FONT STYLE="white-space:nowrap">cut-off</FONT> date: 16&nbsp;April 2021) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="32%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Part A 1st line NSCLC<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Part C 2nd line HNSCC<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tumour Response Best Overall<BR>Response (BOR) per
iRECIST</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stages&nbsp;1&nbsp;&amp;&nbsp;2&nbsp;N&nbsp;(%)<BR>Total&nbsp;N=36</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stage&nbsp;1&nbsp;&amp;&nbsp;2&nbsp;N&nbsp;(%)<BR>Total&nbsp;N=37</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Complete Response (CR)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2 (5.6)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5 (13.5)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Partial Response (PR)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">13 (36.1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6 (16.2)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stable Disease (SD)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10 (27.8)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3 (8.1)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Progressive Disease (PD)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6 (16.7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">17 (45.9)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Not Evaluable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5 (13.9)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">6 (16.2)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Disease Control Rate (DCR)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>25 (69.4)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>14 (37.8)</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Objective&nbsp;Response&nbsp;Rate&nbsp;(ORR)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>15 (41.7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>11 (29.7)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ORR in evaluable pts</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>15 (48.4), N=31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>11 (35.5), N=31</B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Findings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1st line
NSCLC - Part A </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sustained and durable responses: 15 patients with responses giving an ORR of 41.7% on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intention-to-treat</FONT></FONT> basis and 48.4% in evaluable patients, as assessed by blinded independent committee read </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As assessed by Blinded Independent Central Review (BICR) </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As assessed by local investigator read </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160476g26d87.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">None of the patients with a confirmed response progressed within 6 months and the median duration of response
(DoR) is currently estimated to be more than 13 months in patients unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2/36 (5.6%) patients had a Complete Response (complete disappearance of tumour lesions) and 23/36 (63.9%) of
patients had a target lesion decrease (includes the 2 CRs) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durable responses observed in all <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups as assessed by local
investigator read,<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> for example: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR in the <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1% <FONT STYLE="white-space:nowrap">PD-L1</FONT>
subgroup was 44.0% (11/25) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR in the &lt; 50% <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroup was 31.6% (6/19)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR in the <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% <FONT STYLE="white-space:nowrap">PD-L1</FONT>
subgroup was 53.8% (7/13) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Median overall PFS is 8.2 months in patients unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression, as assessed by local investigator read. This is very promising for a chemo-free 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line regimen. Median PFS increases to 11.8 months in the
<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroup and median PFS in the &lt; 1% <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroup is 4.1 months </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusion:</B> The data presented for 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line NSCLC is very encouraging and will be broadened by the
ongoing recruitment in this patient population to form a solid basis for late-stage clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2nd line HNSCC - Part C </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11 patients with responses giving an ORR of 29.7% on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">intention-to-treat</FONT></FONT> basis and 35.5% in evaluable patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durable responses with now 5 patients (13.5%) having a Complete Response. So far median duration of response is
not yet reached. None of the patients with a response progressed within 6 months </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, median PFS is 2.1 months and
median OS is 12.6 months </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In patients in <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1
subgroup (N=24), ORR is 45.8%, median PFS is 4.1 months, and median OS is 12.6 months </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusion</B>: The 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> line HNSCC data is mature and continues to be very encouraging and forms an excellent basis to move into the 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> line HNSCC indication via
Immutep&#146;s randomised Phase IIb <FONT STYLE="white-space:nowrap">TACTI-003</FONT> study which is expected to start in <FONT STYLE="white-space:nowrap">mid-2021.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2nd line NSCLC - Part B </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stage 1 results were reported in
November 2020 at SITC and Overall Survival is trending favourably. Stage 2 recently opened for patient enrolment and combined results from Stages 1 &amp; 2 are expected to be reported later this year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safety </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination treatment continues to be safe
and well tolerated with no new safety signals reported thus far. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recruitment Update </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trial recruitment continues to progress well, with 127 patients out of up to 183 already participating at 12 clinical sites across Australia, Europe, the UK
and US. At present, recruitment is ongoing for the expansion stage of Part A and Stage 2 of Part B. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As assessed by local investigator read and in evaluable patients only </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160476g26d87.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruitment details for each Part of the trial are
shown below and are current as at 1&nbsp;June 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Table 2</I> &#150; <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Recruitment (as at
1&nbsp;June 2021) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stage 1 (N)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Actual / Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stage 2 (N)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Actual / Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Recruitment</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Status</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expansion Stage</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Actual / Target</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Part A (1st line NSCLC)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">17/17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">19/19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">EXPANDED</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23/74</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Part B (2nd line NSCLC)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">23/23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">RECRUITING</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Part C (2nd line HNSCC)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">18/18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21/19<SUP STYLE="font-size:85%; vertical-align:top">4</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">COMPLETE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
currently expects to report further interim data from Part A, final data from Part C, and new results from Stages 1 &amp; 2 of Part B in 2H calendar year 2021 or early calendar year 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast Details </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will present this data in a
global webcast for investors. Details are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date&nbsp;&amp; Time: </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Thursday, 10&nbsp;June 2021, at 7:00 am Australian Eastern Daylight Time (AEDT) (Wednesday, 9&nbsp;June, at 5:00 p.m. U.S. ET) </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Register: </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>https://fnn.webex.com/fnn/onstage/g.php?MTID=ebcdb72840d84111e57730c2b6cccd2c1</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Questions: </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Investors are invited to submit questions in advance via <U>immutep@citadelmagnus.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A replay of the webcast will also be available at <U>www.immutep.com</U> from the day after the event. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">TACT-002</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Two ACTive Immunotherapies) is being conducted in collaboration with Merck&nbsp;&amp; Co., Inc., Kenilworth,
NJ, USA (known as &#147;MSD&#148; outside the United States and Canada). The study is evaluating the combination of efti with MSD&#146;s KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in up to 183 patients with
second line head and neck squamous cell carcinoma or <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer in first and second line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
trial is a Phase II, Simon&#146;s <FONT STYLE="white-space:nowrap">two-stage,</FONT> <FONT STYLE="white-space:nowrap">non-comparative,</FONT> open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> multicentre clinical study that is taking
place in study centres across Australia, Europe, the UK and US. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Two extra patients were treated as allowed under the trial protocol since 2 patients had dropped out due to <FONT
STYLE="white-space:nowrap">Covid-19</FONT> prior to first post-baseline staging. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g160476g26d87.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients participate in one of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part A - First line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer (NSCLC), <FONT
STYLE="white-space:nowrap">PD-X</FONT> naive </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part B - Second line NSCLC, <FONT STYLE="white-space:nowrap">PD-X</FONT> refractory </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Part C - Second line Head and Neck Squamous Cell Carcinoma (HNSCC), <FONT STYLE="white-space:nowrap">PD-X</FONT>
naive </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> is an <FONT STYLE="white-space:nowrap">all-comer</FONT> study in terms of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression is typically reported in three groups
for NSCLC: &lt; 1%, <FONT STYLE="white-space:nowrap">1-49%</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 50% (Tumour Proportion Score or TPS) and in HNSCC: &lt;&nbsp;1, <FONT STYLE="white-space:nowrap">1-19</FONT> and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;20 (Combined Positive Score or CPS). Patients with a high <FONT STYLE="white-space:nowrap">PD-L1</FONT> status are typically more responsive to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy such as pembrolizumab, whereas those with low <FONT STYLE="white-space:nowrap">PD-L1</FONT> status are overall significantly less responsive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">More information about the trial can be found on Immutep&#146;s website or on ClinicalTrials.gov (Identifier: NCT03625323) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products,
including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be
found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g160476g26d87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g160476g26d87.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (8#( ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHIIR,_I0!7UG4H]'TZ:ZF;9#;H9)&]% R:\6_9A
M_;V\!_M7>*-5TGPM<7[7NEH)BES#L$T1)&]3DY''?!KV/Q%!;ZAI$\-UM-K(
MA296Z,A&"#7A7[)/[)7PO_9_\6ZUJ7@G8]]J2;2/M#2F"+).U<DXY/)'7 I7
MUL2YQ346]6?0M%8VO>-]-\,Q,VH7UO:;1G$D@#$#OCK7&V7[6?@2_P!4CL8O
M$%JUPY"X(89/UQBES1O:Y$J].+M*23]3TNBL?6/&NF^'M):^O+ZUAM50R>8T
M@P5'.1Z_A7-^"?VC/"'Q'O9+?2-<MKB:/[RGY,?]]8S1S*]ARK4XNSDKG>45
M"+G/Y9_"N:\6_&CPWX'@634M7M+=2<??#'\AFG*22NPG4C#6;L=717">#/VC
M?"/Q!U$VNE:W:SS*,E6)3CVW8K2\:_&'P]\.X(Y-7U2VM5DX4%MQX]AS2YD3
M]8I<O-S*QU-%<MX#^+V@_$BWEDT75+>^6%L. =I7\#R:V]6UF'2--EO+B9;>
MVA4O)(YPJJ.I----71I"2EK$O45B^$OB!I'C<S#2]0M;[[,0)?)<-LSTS^5)
MXG^(&D^"HXY-6O[>Q29MD9E8*&8>E,HU9&V,Q9NE-6ZC\T+YBE\9V;OF ]<5
MSVL^*+/Q3\.]4OM)O$N(_LLICGB?[K!2<@^HK\W/^"2'QIU;5OVDM6N/%7BS
M5KZW71IOFU347F4$2#IO;K0!^I2<GG]*=7-^&?BGX?\ %%^UIIVJV=Y<*AE,
M<4@9@OK6Y<7BP(S-(L:*,EF. /K0!8HKR3Q5^VW\,_"GB1M'O/%=E!?1ML90
MI<9SCJ!BO2=%\36?B*P2ZL;B&ZMY,$/&X88_"@#2J-A@9K+\2^/-)\'6$EQJ
MFH6EE'$I<^;(%) ZX'4_A7FL7[=?PMGU/[&OBRS^T%L;2C 9],XH\P.&_P""
MGOA74?%'P%M);%&>/2]1CO+G:>D2JV6/TKQ[]@?X_:;\/=0\13>+]0OOL\D4
M3PWMR[3+%C=E >2,Y' ]*^X+B+2O'7AV:%C9ZGI]Y&8Y5#"6.12.AZCI7Q[\
M4O\ @G!XN@L[C2_!^L:7-X5N;TZ@NGW@,<EM)R %<!B0 <<D5YN*HS4_:P/F
M<SP>(ABUC<.N9VUC^1R?[:WQ2\+?M'^)+&[\-ZC;0CP[:S/,]Q$4^W;BNT1D
M Y(VG[V/O5[%_P $LO#EYI/P1U.XN$DCAOM3>:W4]UVK\P^M>;_#K_@EWXAN
MM;AF\5:KIMEIL+JSV]H6E:X&>4.0NT'U%?;7A;PQ:>$]#M=-L(8[6SLHUBAA
MC&%1 , 48:A.5;VU3<PR? 8B>)ECL3'E?1&I&,"G445Z1]:%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3G#>8_RGW%?J?\/HGMO FD12_P"MCM(E?G/.T4!N:R0\<\TI3Y>M.4?W?UI
M?6@.MQXZ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ)937=E<1W%O!*87D4<!QU!K+\%?''PW\1M:NM/TF\:ZN+,$RKY+H%P<<$@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3)O#GPYT.QNU\NZL[.*WE0'[KA0"*Z#8.G?'IS0L?)^51W% $E%%% !1110
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MT?\ #K"^_P"@]'^?_P!C1[;&_P B#ZWGO_/M'L?_  \7^%?_ $'KC_P G_\
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M\ )__B*/^'B_PK_Z#UQ_X 3_ /Q%>.?\.L+[_H/1_G_]C1_PZPOO^@]'^?\
M]C1[;&_R(/K>>_\ /M'L?_#Q?X5_]!ZX_P# "?\ ^(H_X>+_  K_ .@]<?\
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M /8T?\.L+[_H/1_G_P#8T>VQO\B#ZWGO_/M'L?\ P\7^%?\ T'KC_P  )_\
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M[1['_P /%_A7_P!!ZX_\ )__ (BC_AXO\*_^@]<?^ $__P 17CG_  ZPOO\
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M /8T?\.L+[_H/1_G_P#8T>VQO\B#ZWGO_/M'L?\ P\7^%?\ T'KC_P  )_\
MXBE'_!1GX5K_ ,QZX_\  "?_ .)KQO\ X=87W_0>C_/_ .QIK?\ !+"^S_R'
MH_S_ /L:/;8W^1!];SW_ )]H]F_X>-_"O_H/7'_@!/\ _$T?\/&_A7_T'KC_
M , )_P#XFO&E_P""6-]GG7H_S_\ L:7_ (=8WG_0>3\__L:/;8W^0/K6>?\
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M]IOSHHH /LG^TWYT?9/]IJ** #['_M-1]C_VFHHH /LG^TWYT?9/]IOSHHH
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MVF_.BB@ ^R?[3?G1]D_VF_.BB@ ^R?[3?G1]D_VFHHH /L?^TU'V/_::BB@
M^Q_[34?8_P#::BB@ ^R?[34?9/\ :;\Z** #[)_M-^='V3_:;\Z** #[)_M-
M^='V3_:;\Z** #[)_M-^='V3_:;\Z** #[)_M-^='V3_ &F_.BB@ ^R?[3?G
M1]D_VF_.BB@ ^R?[3?G1]D_VF_.BB@ ^R?[3?G1]D_VF_.BB@ ^R?[34?9/]
'MJ** L?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
